XSpray Pharma (Sweden) Top Management

XSPRAY Stock  SEK 30.15  1.55  4.89%   
XSpray Pharma employs about 26 people. The company is managed by 9 executives with a total tenure of roughly 61 years, averaging almost 6.0 years of service per executive, having 2.89 employees per reported executive. Analysis of XSpray Pharma's management performance can provide insight into the company performance.
Kerstin Hasselgren  Insider
Chief Officer
Per Andersson  Insider
Chief Officer
  
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XSpray Pharma AB. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

XSpray Pharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.1448) % which means that it has lost $0.1448 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2423) %, meaning that it generated substantial loss on money invested by shareholders. XSpray Pharma's management efficiency ratios could be used to measure how well XSpray Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
100%

XSpray Pharma Workforce Comparison

XSpray Pharma AB is rated fourth in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 361. XSpray Pharma holds roughly 26.0 in number of employees claiming about 7% of stocks in Biotechnology industry.
JavaScript chart by amCharts 3.21.15OthersVICOCANTABIOA-BHNSAXSPRAY

XSpray Pharma AB Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. XSpray Pharma AB Price Series Summation is a cross summation of XSpray Pharma price series and its benchmark/peer.
JavaScript chart by amCharts 3.21.15Dec2025FebJan 27FebFeb 10Feb 17Feb 24Mar3132333435 10K20K30K40K50K60K 606264666870 3132333435 Show all
JavaScript chart by amCharts 3.21.15XSpray Pharma AB Volume XSpray Pharma AB Closing Prices Xbrane Biopharma Closing Prices - Benchmark XSpray Pharma AB Price Series Summation

XSpray Pharma Notable Stakeholders

A XSpray Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as XSpray Pharma often face trade-offs trying to please all of them. XSpray Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting XSpray Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.

About XSpray Pharma Management Performance

The success or failure of an entity such as XSpray Pharma AB often depends on how effective the management is. XSpray Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of XSpray management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the XSpray management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Xspray Pharma AB engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Xspray Pharma AB was founded in 2003 and is based in Solna, Sweden. Xspray Pharma is traded on Stockholm Stock Exchange in Sweden.
Please note, the presentation of XSpray Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, XSpray Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of XSpray Pharma's management manipulating its earnings.

XSpray Pharma Workforce Analysis

Traditionally, organizations such as XSpray Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare XSpray Pharma within its industry.

XSpray Pharma Manpower Efficiency

Return on XSpray Pharma Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee3.7M
Net Loss Per Executive10.7M

Complementary Tools for XSpray Stock analysis

When running XSpray Pharma's price analysis, check to measure XSpray Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XSpray Pharma is operating at the current time. Most of XSpray Pharma's value examination focuses on studying past and present price action to predict the probability of XSpray Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XSpray Pharma's price. Additionally, you may evaluate how the addition of XSpray Pharma to your portfolios can decrease your overall portfolio volatility.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities